来自抗癌前线的报道：用病人的癌细胞处理后激活免疫系统

Figure Tumor rejection antigens are specific to individual tumors

Mice immunized with an irradiated tumor and challenged with viable cells of the same tumor can, in some cases, reject a lethal dose of that tumor (left panels). This is the result of an immune response to tumor rejection antigens. If the immunized mice are challenged with viable cells of a different tumor, there is no protection and the mice die (right panels).

多年前的动物模型已经发展到临床试验。UPenn 和Novartis 正在做这方面的临床试验。做法是把病人的癌细胞取出来，用辐射灭活，再注射到病人体内（腹部的脂肪中）。灭活的癌细胞依然可以触发免疫反应。激活后的免疫系统可以攻击原发的癌细胞。

几个变种：（1）与分子免疫疗法联用（PD-1，CTLA4）。（2）对灭活的癌细胞进一步处理再注入体内。
 

GVAX is portfolio of irradiated tumor cell lines that have been engineered to recruit immune cells by expressing GM-CSF, the most potent immune cell recruitment factor. GVAX vaccines are well suited for combination therapy because (a) they present numerous antigens to the immune system, thereby enabling a broad-based immune response and (b) have a well-established, favorable safety profile demonstrated in multiple clinical trials.

 

所有跟帖： 

• GVAX vaccine 因为用Tumor Cell lines 引发在三期临床试验时严重的付作用. 原公司Cell genes -尚德仕- ♂ (85 bytes) () 11/18/2014 postreply 21:31:32